Curachem was founded in 2009 and is a contract R&D company that synthesizes radiolabeled compounds using isotopes. The compounds, labeled with carbon-14 (14C) and tritium (3H), are used in absorption, distribution, metabolism and excretion (ADME) studies during drug development.
Disclosed revenue is concentrated in radiolabeled compound synthesis, and the experimental brokerage service line has generated no sales since 2021. Its customers are centered on multinational pharmaceutical companies in the United States and Europe.
Its trust-based relationships with Japanese drug developers have been described as a barrier that new entrants find difficult to overcome. In Korea, where domestic ADME evaluation providers were previously scarce, the company has been viewed as filling that gap.
A 2021 report said the company passed an EU GMP on-site audit by ICON, the global CRO formerly known as PRA, which supports its clinical trial material supply capability.
The business requires government licensing and biennial inspections for handling radioactive materials, yet its capital-light model means entry barriers are not considered high.
Compared with a large CDMO such as Samsung Biologics, its business model and scale differ markedly, and Curachem is a small specialist focused on research-grade labeled compounds. On the supply side, 14C depends on overseas reactor output, and a 2021 report cited this as a constraint on operations.